| Literature DB >> 26103488 |
Marloes Jeulink1, Max Dahele, Philip Meijnen, Ben J Slotman, Wilko F A R Verbakel.
Abstract
Not all clinics have breath-hold radiotherapy available for left-breast irradiation. However intensity-modulated radiotherapy (IMRT) has also been advocated as a means of lowering heart doses. There is currently no large-scale, long-term follow-up data after breast IMRT and, since dose distributions may differ from classic tangent-based radiotherapy, caution is needed to avoid unexpected worsening of the late toxicity profile. We compared four IMRT techniques for free-breathing left-breast irradiation. Consistent with the aforementioned concerns, our goal in planning was to prioritize organ at risk (OAR) sparing in a way that mimicked tangent-based radiotherapy. Ten simultaneous integrated boost treatment plans (PTVelective = 15 × 2.67 Gy; PTVboost = 15 × 3.35 Gy) were created using 1) hybrid-IMRT (H-IMRT), 2) full IMRT (F-IMRT), and 3) volumetric-modulated arc therapy with two partial arcs (2ARC) and 4) six partial arcs (6ARC). Reduction in OAR mean and low dose was prioritized. End-points included OAR sparing (e.g., heart, left anterior descending artery [LAD+3 mm], lungs, and contralateral breast) and PTV coverage/dose homogeneity. Under these conditions we found the following: 1) H-IMRT provided the best mean and low dose OAR sparing, PTVelective coverage (mean V95% = 98%), PTVboost coverage (V95% = 98%), and PTV homogeneity. However, it delivered most intermediate-high dose to the heart, LAD+3 mm and ipsilateral lung; 2) 6ARC had the best intermediate-high dose sparing, followed by F-IMRT, but this was at the expense of more dose in the contralateral lung and breast and worse PTV coverage (PTVelective mean V95% = 96%/97% and PTVboost mean V95% = 91%/96% for 6ARC/F-IMRT). When trying to spare mean and low dose to OARs, the preferred IMRT technique for left-breast irradiation without breath-hold was H-IMRT. This is currently the standard solution in our institution for left-breast radiotherapy under free-breathing and breath-hold conditions.Entities:
Mesh:
Year: 2015 PMID: 26103488 PMCID: PMC5690145 DOI: 10.1120/jacmp.v16i3.5266
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1Planning target volume (PTV) and organ‐at‐risk structures .
Figure 2Typical beam/arc arrangements for the various techniques used in this study. The planning target volume (PTV) of the breast is outlined with a medial boost (shaded): (a) Hybrid IMRT (H‐IMRT); (b) Full IMRT (F‐IMRT); (c) 2 Arc RapidArc (2ARC); (d) 6 Arc RapidArc (6ARC).
Comparison of planning target volume (PTV) and organ‐at‐risk (OAR) dosimetry .
|
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| 101.8 | 0.5 | 102.4 | 0.3 | 0.02 | 101.2a | 2.6 | 0.44 | 102.3 | 0.3 | 0.04 |
|
| 3.5a | 0.6 | 3.7 | 0.4 | 0.31 | 4.1 | 0.8 | 0.04 | 3.7 | 0.3 | 0.44 |
|
| 98.0a | 0.7 | 96.5 | 0.7 | 0.01 | 91.9 | 3.7 | 0.01 | 96.0 | 1.3 | 0.01 |
|
| 7.4a | 3.5 | 11.0 | 3.5 | 0.03 | 12.5 | 5.5 | 0.02 | 12.0 | 3.7 | 0.05 |
|
| 100.1 | 0.9 | 100.0a | 0.8 | 0.65 | 100.6 | 1.2 | 0.33 | 100.3 | 0.9 | 0.24 |
|
| 2.3a | 0.4 | 2.7 | 0.7 | 0.11 | 3.9 | 1.0 | 0.01 | 4.2 | 2.1 | 0.01 |
|
| 97.9a | 1.7 | 95.9 | 3.0 | 0.02 | 91.2 | 6.0 | 0.01 | 90.9 | 7.4 | 0.01 |
|
| 0.0a | 0.0 | 0.5 | 0.7 | 0.04 | 3.6 | 4.3 | 0.01 | 2.8 | 3.5 | 0.01 |
| Heart mean dose (Gy) | 3.8a | 1.8 | 4.8 | 1.9 | 0.09 | 5.0 | 1.5 | 0.03 | 3.9 | 1.9 | 0.96 |
| Heart V5 (%) | 23.0a | 16.1 | 28.1 | 19.9 | 0.51 | 31.8 | 17.7 | 0.17 | 25.5 | 23.6 | 0.96 |
| Heart V10 (%) | 6.4 | 8.8 | 8.8 | 9.9 | 0.72 | 9.3 | 7.3 | 0.09 | 5.7a | 6.8 | 0.31 |
| Heart V20 (%) | 2.9 | 2.7 | 1.6 | 2.0 | 0.07 | 1.4 | 1.7 | 0.01 | 0.5a | 0.9 | 0.01 |
| Heart V30 (%) | 1.9 | 1.9 | 0.2 | 0.3 | 0.01 | 0.2 | 0.4 | 0.01 | 0.0a | 0.1 | 0.01 |
|
| 3.0 | 2.8 | 1.6 | 1.7 | 0.05 | 1.7 | 1.7 | 0.03 | 1.0a | 1.5 | 0.01 |
|
| 2.4 | 2.6 | 0.1a | 0.3 | 0.02 | 0.3 | 0.8 | 0.02 | 0.1a | 0.4 | 0.02 |
| IL mean dose (Gy) | 6.5 | 2.3 | 6.1 | 1.3 | 0.45 | 7.1 | 1.5 | 0.17 | 5.1a | 83.0 | 0.04 |
| IL V5 (%) | 26.7 | 9.3 | 34.0 | 12.6 | 0.02 | 40.4 | 11.4 | 0.01 | 24.7a | 4.3 | 0.24 |
| IL V20 (%) | 11.7 | 5.5 | 7.0 | 2.0 | 0.01 | 9.1 | 3.4 | 0.07 | 6.0a | 2.2 | 0.01 |
| IL V30 (%) | 8.7 | 4.9 | 2.6 | 1.3 | 0.01 | 2.8 | 1.9 | 0.01 | 1.7a | 1.2 | 0.01 |
| CL mean dose (Gy) | 0.5a | 0.3 | 1.2 | 0.3 | 0.01 | 1.7 | 3.8 | 0.01 | 1.8 | 0.7 | 0.01 |
| CB mean dose (Gy) | 0.6a | 0.3 | 1.6 | 0.2 | 0.01 | 2.4 | 0.4 | 0.01 | 2.4 | 0.4 | 0.01 |
| CB V5 (%) | 1.3a | 1.4 | 4.1 | 1.6 | 0.01 | 6.7 | 2.3 | 0.01 | 6.8 | 2.7 | 0.01 |
| CB V10 (%) | 0.4 | 0.7 | 0.2 | 0.3 | 0.67 | 0.1a | 0.3 | 0.07 | 0.3 | 0.6 | 0.89 |
| Body V5 (cc) | 2416.0a | 1061.9 | 3259.3 | 1414.6 | 0.01 | 4227.4 | 2097.3 | 0.01 | 3445.3 | 1487.5 | 0.01 |
| MU | 698.1 | 98.7 | 1546.9 | 320.0 | 0.01 | 729.5 | 62.9 | 0.20 | 902.8 | 86.6 | 0.01 |
The most favorable numerical result.
; ; ; ; ; ; ; ; arc therapy (RapidArc) using two partial arcs; ; arc therapy (RapidArc) using 6 short partial arcs; .
Figure 3Mean dose‐volume histograms for planning target volume (PTV) and organs at risk averaged over all patients: (a) ; (b) ; (c) heart; (d) ; (e) ipsilateral lung; (f) contralateral lung; (g) contralateral breast.